Testosterone and Androstanolone in Rat Plasma and Tissues

Total Page:16

File Type:pdf, Size:1020Kb

Testosterone and Androstanolone in Rat Plasma and Tissues View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Volume 33. number 2 FEBS LETTERS July 1973 TESTOSTERONE AND ANDROSTANOLONE IN RAT PLASMA AND TISSUES P. ROBEL, C. CORPECHOT and E.E. BAULIEU Unit& de Recherches sur le Mtftabolisme MoKculaire et la Physio- Pathologic des Stboides de I’lnstitut National de la SantC et de la Recherche M&dicale, UniversitC Paris-&d and Ddpartement de Chimie Bio$gique, HOpital de BicCtre, 78 rue du G&&al Leclerc, 94 Bic&re, France Received 22 April 1973 1. Introduction 2. Material and methods From studies of rat ventral prostate explants in Normal 3 month old Wistar rats, weighing 250- culture, in which testosterone metabolism in the tar- 300 g were used throughout the experiments. They get organ can be correlated with testosterone and tes- were killed by decapitation, and plasma and organ tosterone metabolite activities [ 1,2] , the concept has samples were collected and pooled. 10% Homogen- emerged that testosterone may be largely if not exclu- ates of the organs were made by the use of an ultra- sively active through the formation of metabolic de- Turrax, then 4 vol of ethanol containing tracer rivative(s) formed in situ. Parallel investigations have amounts of radioactive testosterone and androstano- indicated that an active dihydro-metabolite of testos- lone were added. After standing at -20°C overnight, terone, androstanolone (17&hydroxy-5a-androstan-3- the precipitate was eliminated and, after evaporation one, also known as dihydro-testosterone, DHT) is ac- under vacuum, the extracts were taken up in water cumulated in bound form in ventral prostate nuclei and extracted by ethyl acetate. [3-51 whereas a prostatic cytosol receptor binds an- The gas chromatographic electron capture tech- drostanolone with a higher affinity than testosterone nique described by Van der Molen and Groen [8] for ]6,71. the measurement of testosterone in human plasma Whether or not androstanolone formation is an was modified in order to allow the measurement of obligatory intermediary step in testosterone activity testosterone and dihydro-testosterone in rat plasma in the prostate itself and in other androgen responsive and tissue samples. The ethyl acetate extract was structures is still undecided, and therefore a systemat- dried, redissolved in hexane: benzene (1: 1) and ap ic measurement of testosterone and androstanolone plied to a silica gel column [9] , followed by a silica in selected organs of normal adult male rats has been gel thin-layer chromatography in the benzene:acetone undertaken as a first approach for understanding the (85: 15) system (2 migrations) [2] . Testosterone and physiological situation. It is believed that the local androstanolone were located using a radiochromato- concentration of active steroids might be related to gram scanner, and eluted. Then the heptafluorobutyr- the presence and the binding characteristics of high ates of testosterone and androstanolone were formed, affinity receptors possibly involved in hormone action. purified by thin-layer chromatography, and measured by gas liquid chromatography with electron capture detection [lo] . 2Ofl-OH-pregn-4-ene-3-one hepta- fluorobutyrate was used as internal standard for tes- tosterone heptafluorobutyrate, and testosterone hep- tafluorobutyrate was used as internal standard for * Postal address: Lab Hormones, F 94 Bicetre, France. androstanolone heptafluorobutyrate. The limit of 218 North-Holland Publishing Company - Amsterdam Volume 33, number 2 FEBS LETTERS July 1973 Table 1 Testosterone and androstanolone in rat plasma and tissues’. of testosterone So-reductase [ 141 and the relatively high affinity of the cytosol androstanolone receptor Testosterone Androstanolone for testosterone (0.2-0.5 that for androstanolone) Plasma 2.5 f o.32 < o.23 [7] . In addition, it is not known whether both ster- Seminal vesicles 2.2 f 0.3 3.0 f 0.64 oids are evenly distributed throughout different cell Ventral prostate 2.0 + 0.4 2.8 + OS4 types. Levator ani muscle 7.9 f OS4 Q 0.2 In muscles no androstanolone is found, including Thigh muscles 2.9 * 0.5 Q 0.4 in the Zevatorani, a classical androgen dependent or- Hypothalamus 13.7 f 2.04 2.0 ?r o.44 gan. Testosterone concentration is higher than in the Pituitary gland 60.5 f 5.54 <6 plasma, a finding to be correlated with the presence Brain parietal cortex 1.3 ?I 0.15 Q 0.4 of a cytosol receptor in the levator ani muscle, having Kidney 12.5 f 0.54 3.0 * 1.14 an affinity for testosterone greater than for andros- Small intestine =z o.24 < 0.2 tanolone [ 151. In skeletal muscles, androgens display ’ rig/g (Organs) or ml (plasma). a well known anabolic action, responsible for the sex- : Mean f SEM. ual difference in their development even they are usu- G Values too low to be measured accurately. Their upper ally not considered as typical secondary sex organs. limit is given. The concentration of testosterone in thigh muscles is 4 Significantly different from corresponding plasma values P G 0.01. of the order of that found in the plasma, whereas in ’ Significantly different from corresponding plasma values control tissues as intestine or brain cortex the value P < 0.2. is definitely lower. Therefore it might be possible that skeletal muscles contain a testosterone binding pro- sensitivity of the method is 0.4 ng of steroid. The tein, possibly of feeble abundance and/or difficult to overall recovery of added tracers is 20-30%. Thus solubilize and which may be therefore very difficult the initial 5 g (ml) of tissue (plasma) sample should to demonstrate [ 151 . It is noteworthy that in muscle contain at least 2 ng of steroid for processing through cells which exhibit a purely hypertrophic response to the entire procedure. All measurements were done in testosterone, no androstanolone is found, whereas triplicate. The coefficient of variation for plasma tes- this latter compound has an hyperplastic activity pre- tosterone samples was found to be 10% [lo] . viously documented in prostate experiments [ 11. In several other organs, kidney, hypothalamus and pituitary, there is also testosterone accumulation, 3. Results and discussion whereas androstanolone is present in a relatively small concentration. As in the muscle, testosterone The concentrations of testosterone and dihydrotes- itself may also be implicated in androgen action on tosterone were measured in rat plasma, seminal vesi- (mice) kidney [ 161. In the hypothalamus and pitu- cles and prostate, Zeuatorani and thigh muscles, hypo- itary, the nature of the steroid molecule(s) regulating thalamus, pituitary gland and brain parietal cortex, the synthesis and secretion of gonadotropin releasing kidney and small intestine (table 1). hormone(s) and gonadotropins is (are) still controver- In the plasma, testosterone is present at a concen- sial. The present results suggest a role for testosterone tration similar to those previously reported [ 1 l- 131, itself, whereas arguments have been brought recently whereas androstanolone is not detected. in favor of reduced [ 17-191 or oestrogen [20] me- In ventral prostate and seminal vesicles, androstano- tabolites of testosterone. lone is found at a slightly greater concentration than There is possibly some interest that a regulatory testosterone, which is itself in amount similar to that molecule has to proceed through several transforma- in the plasma. The fact that testosterone concentra- tion steps before being active, and the formation of tion approaches that of androstanolone is rather unex- different active metabolite(s) in target organs may un- pected, although testosterone accumulation in pros- dergo a subtle regulation. This mechanism offers the tate cells might be favored by the relatively high K, possibility of selective pharmacodynamic or therapeu- 219 Volume 33, number 2 FEBS LETTERS July 1973 tic approaches. Testosterone might be a “hormone” [ 21 P. Robel, I. Lasnitzki and E.E. Baulieu, Biochimie 53 in the muscles and in some cells of the kidney, the (1971) 81. [ 31 K.D. Anderson and S. Liao, Nature 219 (1968) 277. hypothalamus and the pituitary, whereas it would be [4] N. Bruchovsky and J.D. Wilson, J. Biol. Chem. 243 a “prehormone” elsewhere, the active molecule being (1968) 2012. androstanolone in the prostate and the seminal vesi- [S] I. Jung and E.E. Baulieu, Biochimie 53 (1971) 807. cle and possibly also an oestrogen in the hypothala- [6] W.I.P. Mainwaring, J. Endocrinol. 45 (1969) 333. mus. Therefore selective analogues or antagonists [7] E.E. Baulieu and I. Jung, Biochem. Biophys. Res. Commun. 38 (1970) 599. could be devised in order to act upon the correspond- [ 81 H.J. Van der Molen and D. Groen, in: Gas-liquid ing target tissues, thus using the metabolism of testos- chromatography of steroids, ed. J.K. Grant, Memoir of terone as a molecular basis to dissociate its overall ef- Society for Endocrinology, Nr. 16 (1967) p. 155. fects. [ 91 P. Rot&, These Doctorat &s-Sciences, Paris (1967) p. 11. [lo] C. Corpechot and P. Robel, in preparation. [ll] B.J. Lloyd, J. Endocrinol. 54 (1972) 285. [ 121 K.J. Tveter and A. Aakvag, Acta Endocrinol. 65 (1970) Acknowledgements 723. [ 131 L. Buric, H. Becker, C. Peterson and K.D. Voigt, Acta The authors acknowledge the financial help of the Endocrinol. 69 (1972) 153. Ford Foundation, the Centre National de la [ 141 A.B. Roy, Biochimie 53 (1971) 1031. [ 151 I. Jung and E.E. Baulieu, Nature New Biology, 237 Recherche Scientifique, the Ligue Nationale (1972) 24. Franqaise contre le Cancer and Roussel-UCLAF. The [ 161 L.P. Bullock and C.W. Bardin, J. Clin. Endocrinol. skillful assistance of B. Leclaire, L. Helie, S. Rouzaud Metab. 35 (1972) 935. and P: Toubkis is acknowledged. [ 171 F.F.G. Rommerts and H.J. Van der Molen, Biochim. Biophys. Acta 248 (1971) 489.
Recommended publications
  • Campro Catalog Stable Isotope
    Introduction & Welcome Dear Valued Customer, We are pleased to present to you our Stable Isotopes Catalog which contains more than three thousand (3000) high quality labeled compounds. You will find new additions that are beneficial for your research. Campro Scientific is proud to work together with Isotec, Inc. for the distribution and marketing of their stable isotopes. We have been working with Isotec for more than twenty years and know that their products meet the highest standard. Campro Scientific was founded in 1981 and we provide services to some of the most prestigious universities, research institutes and laboratories throughout Europe. We are a research-oriented company specialized in supporting the requirements of the scientific community. We are the exclusive distributor of some of the world’s leading producers of research chemicals, radioisotopes, stable isotopes and environmental standards. We understand the requirements of our customers, and work every day to fulfill them. In working with us you are guaranteed to receive: - Excellent customer service - High quality products - Dependable service - Efficient distribution The highly educated staff at Campro’s headquarters and sales office is ready to assist you with your questions and product requirements. Feel free to call us at any time. Sincerely, Dr. Ahmad Rajabi General Manager 180/280 = unlabeled 185/285 = 15N labeled 181/281 = double labeled (13C+15N, 13C+D, 15N+18O etc.) 186/286 = 12C labeled 182/282 = d labeled 187/287 = 17O labeled 183/283 = 13C labeleld 188/288 = 18O labeled 184/284 = 16O labeled, 14N labeled 189/289 = Noble Gases Table of Contents Ordering Information.................................................................................................. page 4 - 5 Packaging Information ..............................................................................................
    [Show full text]
  • COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone During SARS-Cov-2 Infection
    pharmaceuticals Review COVID-19—The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection Katarzyna Kotfis 1,* , Kacper Lechowicz 1 , Sylwester Drozd˙ zal˙ 2 , Paulina Nied´zwiedzka-Rystwej 3 , Tomasz K. Wojdacz 4, Ewelina Grywalska 5 , Jowita Biernawska 6, Magda Wi´sniewska 7 and Miłosz Parczewski 8 1 Department of Anesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; [email protected] 2 Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 3 Institute of Biology, University of Szczecin, 71-412 Szczecin, Poland; [email protected] 4 Independent Clinical Epigenetics Laboratory, Pomeranian Medical University, 71-252 Szczecin, Poland; [email protected] 5 Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 6 Department of Anesthesiology and Intensive Therapy, Pomeranian Medical University in Szczecin, 71-252 Szczecin, Poland; [email protected] 7 Clinical Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, 70-111 Szczecin, Poland; [email protected] 8 Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University in Szczecin, 71-455 Szczecin, Poland; [email protected] * Correspondence: katarzyna.kotfi[email protected]; Tel.: +48-91-466-11-44 Abstract: In March 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was declared Citation: Kotfis, K.; Lechowicz, K.; a global pandemic by the World Health Organization (WHO). The clinical course of the disease is Drozd˙ zal,˙ S.; Nied´zwiedzka-Rystwej, unpredictable but may lead to severe acute respiratory infection (SARI) and pneumonia leading to P.; Wojdacz, T.K.; Grywalska, E.; acute respiratory distress syndrome (ARDS).
    [Show full text]
  • Effect of Dehydroepiandrosterone and Testosterone Supplementation on Systemic Lipolysis
    ORIGINAL ARTICLE Effect of Dehydroepiandrosterone and Testosterone Supplementation on Systemic Lipolysis Ana E. Espinosa De Ycaza, Robert A. Rizza, K. Sreekumaran Nair, and Michael D. Jensen Division of Endocrinology, Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905 Downloaded from https://academic.oup.com/jcem/article/101/4/1719/2804555 by guest on 24 September 2021 Context: Dehydroepiandrosterone (DHEA) and T hormones are advertised as antiaging, antiobe- sity products. However, the evidence that these hormones have beneficial effects on adipose tissue metabolism is limited. Objective: The objective of the study was to determine the effect of DHEA and T supplementation on systemic lipolysis during a mixed-meal tolerance test (MMTT) and an iv glucose tolerance test (IVGTT). Design: This was a 2-year randomized, double-blind, placebo-controlled trial. Setting: The study was conducted at a general clinical research center. Participants: Sixty elderly women with low DHEA concentrations and 92 elderly men with low DHEA and bioavailable T concentrations participated in the study. Interventions: Elderly women received 50 mg DHEA (n ϭ 30) or placebo (n ϭ 30). Elderly men received 75 mg DHEA (n ϭ 30),5mgT(nϭ 30), or placebo (n ϭ 32). Main Outcome Measures: In vivo measures of systemic lipolysis (palmitate rate of appearance) during a MMTT or IVGTT. Results: At baseline there was no difference in insulin suppression of lipolysis measured during MMTT and IVGTT between the treatment groups and placebo. For both sexes, a univariate analysis showed no difference in changes in systemic lipolysis during the MMTT or IVGTT in the DHEA group and T group when compared with placebo.
    [Show full text]
  • Reproductive DHEA-S
    Reproductive DHEA-S Analyte Information - 1 - DHEA-S Introduction DHEA-S, DHEA sulfate or dehydroepiandrosterone sulfate, it is a metabolite of dehydroepiandrosterone (DHEA) resulting from the addition of a sulfate group. It is the sulfate form of aromatic C19 steroid with 10,13-dimethyl, 3-hydroxy group and 17-ketone. Its chemical name is 3β-hydroxy-5-androsten-17-one sulfate, its summary formula is C19H28O5S and its molecular weight (Mr) is 368.5 Da. The structural formula of DHEA-S is shown in (Fig.1). Fig.1: Structural formula of DHEA-S Other names used for DHEA-S include: Dehydroisoandrosterone sulfate, (3beta)-3- (sulfooxy), androst-5-en-17-one, 3beta-hydroxy-androst-5-en-17-one hydrogen sulfate, Prasterone sulfate and so on. As DHEA-S is very closely connected with DHEA, both hormones are mentioned together in the following text. Biosynthesis DHEA-S is the major C19 steroid and is a precursor in testosterone and estrogen biosynthesis. DHEA-S originates almost exclusively in the zona reticularis of the adrenal cortex (Fig.2). Some may be produced by the testes, none is produced by the ovaries. The adrenal gland is the sole source of this steroid in women, whereas in men the testes secrete 5% of DHEA-S and 10 – 20% of DHEA. The production of DHEA-S and DHEA is regulated by adrenocorticotropin (ACTH). Corticotropin-releasing hormone (CRH) and, to a lesser extent, arginine vasopressin (AVP) stimulate the release of adrenocorticotropin (ACTH) from the anterior pituitary gland (Fig.3). In turn, ACTH stimulates the adrenal cortex to secrete DHEA and DHEA-S, in addition to cortisol.
    [Show full text]
  • Safety Data Sheet
    SAFETY DATA SHEET SECTION 1: PRODUCT IDENTIFICATION PRODUCT NAME DHEA (Prasterone) (Micronized) PRODUCT CODE 0733 SUPPLIER MEDISCA Inc. Tel.: 1.800.932.1039 | Fax.: 1.855.850.5855 661 Route 3, Unit C, Plattsburgh, NY, 12901 3955 W. Mesa Vista Ave., Unit A-10, Las Vegas, NV, 89118 6641 N. Belt Line Road, Suite 130, Irving, TX, 75063 MEDISCA Pharmaceutique Inc. Tel.: 1.800.665.6334 | Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8 21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2 MEDISCA Australia PTY LTD Tel.: 1.300.786.392 | Fax.: 61.2.9700.9047 Unit 7, Heritage Business Park 5-9 Ricketty Street, Mascot, NSW 2020 EMERGENCY PHONE CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300 NSW Poisons Information Centre: 131 126 USES Adjuvant; Androgen SECTION 2: HAZARDS IDENTIFICATION GHS CLASSIFICATION Toxic to Reproduction (Category 2) PICTOGRAM SIGNAL WORD Warning HAZARD STATEMENT(S) Reproductive effector, prohormone. Suspected of damaging fertility or the unborn child. May cause harm to breast-fed children. Causes serious eye irritation. Causes skin and respiratory irritation. Very toxic to aquatic life with long lasting effects. AUSTRALIA-ONLY HAZARDS Not Applicable. PRECAUTIONARY STATEMENT(S) Prevention Wash thoroughly after handling. Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dusts or mists. Do not eat, drink or smoke when using this product. Avoid contact during pregnancy/while nursing. Wear protective gloves, protective clothing, eye protection, face protection. Avoid release to the environment. Response IF ON SKIN (HAIR): Wash with plenty of water.
    [Show full text]
  • A10 Anabolic Steroids Hardcore Info
    CONTENTS GENERAL INFORMATION 3 Anabolic steroids – What are they? 4 How do they Work? – Aromatisation 5 More molecules – More problems 6 The side effects of anabolic steroids 7 Women and anabolic steroids 8 Injecting steroids 9 Abscesses – Needle Exchanges 10 Intramuscular injection 11 Injection sites 12 Oral steroids – Cycles – Stacking 13 Diet 14 Where do steroids come from? Spotting a counterfeit 15 Drug Information – Drug dosage STEROIDS 16 Anadrol – Andriol 17 Anavar – Deca-Durabolin 18 Dynabolon – Durabolin – Dianabol 19 Esiclene – Equipoise 20 Primobolan Depot – Proviron – Primobolan orals – Pronobol 21 Sustanon – Stromba, Strombaject – Testosterone Cypionate Testosterone Enanthate 22 Testosterone Propionate – Testosterone Suspension 23 Trenbolone Acetate – Winstrol OTHER DRUGS 24 Aldactone – Arimidex 25 Clenbuterol – Cytomel 26 Ephedrine Hydrochloride – GHB 27 Growth Hormone 28 Insulin 30 Insulin-Like Growth Factor-1 – Human Chorionic Gonadotrophin 31 Tamoxifen – Nubain – Recreational Drugs 32 Steroids and the Law 34 Glossary ANABOLIC STEROIDS People use anabolic steroids for various reasons, some use them to build muscle for their job, others just want to look good and some use them to help them in sport or body building. Whatever the reason, care needs to be taken so that as little harm is done to the body as possible because despite having muscle building effects they also have serious side effects especially when used incorrectly. WHAT ARE THEY? Anabolic steroids are man made versions of the hormone testosterone. Testosterone is the chemical in men responsible for facial hair, deepening of the voice and sex organ development, basically the masculine things Steroids are in a man. used in medicine to treat anaemia, muscle weakness after These masculine effects surgery etc, vascular are called the androgenic disorders and effects of testosterone.
    [Show full text]
  • WO 2018/190970 Al 18 October 2018 (18.10.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/190970 Al 18 October 2018 (18.10.2018) W !P O PCT (51) International Patent Classification: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, CI2Q 1/32 (2006.01) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (21) International Application Number: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, PCT/US2018/021 109 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (22) International Filing Date: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 06 March 2018 (06.03.2018) KM, ML, MR, NE, SN, TD, TG). (25) Filing Language: English Declarations under Rule 4.17: (26) Publication Langi English — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1 7(H)) (30) Priority Data: — as to the applicant's entitlement to claim the priority of the 62/484,141 11 April 2017 ( 11.04.2017) US earlier application (Rule 4.17(Hi)) (71) Applicant: REGENERON PHARMACEUTICALS, Published: INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, — with international search report (Art. 21(3)) New York 10591-6707 (US). — with sequence listing part of description (Rule 5.2(a)) (72) Inventors: STEVIS, Panayiotis; 777 Old Saw Mill Riv er Road, Tarrytown, New York 10591-6707 (US).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • DHEA Sulfate, and Aging: Contribution of the Dheage Study to a Sociobiomedical Issue
    Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue Etienne-Emile Baulieua,b, Guy Thomasc, Sylvie Legraind, Najiba Lahloue, Marc Rogere, Brigitte Debuiref, Veronique Faucounaug, Laurence Girardh, Marie-Pierre Hervyi, Florence Latourj, Marie-Ce´ line Leaudk, Amina Mokranel, He´ le` ne Pitti-Ferrandim, Christophe Trivallef, Olivier de Lacharrie` ren, Stephanie Nouveaun, Brigitte Rakoto-Arisono, Jean-Claude Souberbiellep, Jocelyne Raisonq, Yves Le Boucr, Agathe Raynaudr, Xavier Girerdq, and Franc¸oise Foretteg,j aInstitut National de la Sante´et de la Recherche Me´dicale Unit 488 and Colle`ge de France, 94276 Le Kremlin-Biceˆtre, France; cInstitut National de la Sante´et de la Recherche Me´dicale Unit 444, Hoˆpital Saint-Antoine, 75012 Paris, France; dHoˆpital Bichat, 75877 Paris, France; eHoˆpital Saint-Vincent de Paul, 75014 Paris, France; fHoˆpital Paul Brousse, 94804 Villejuif, France; gFondation Nationale de Ge´rontologie, 75016 Paris, France; hHoˆpital Charles Foix, 94205 Ivry, France; iHoˆpital de Biceˆtre, 94275 Biceˆtre, France; jHoˆpital Broca, 75013 Paris, France; kCentre Jack-Senet, 75015 Paris, France; lHoˆpital Sainte-Perine, 75016 Paris, France; mObservatoire de l’Age, 75017 Paris, France; nL’Ore´al, 92583 Clichy, France; oInstitut de Sexologie, 75116 Paris, France; pHoˆpital Necker, 75015 Paris, France; qHoˆpital Broussais, 75014 Paris, France; and rHoˆpital Trousseau, 75012 Paris, France Contributed by Etienne-Emile Baulieu, December 23, 1999 The secretion and the blood levels of the adrenal steroid dehydro- number of consumers. Extravagant publicity based on fantasy epiandrosterone (DHEA) and its sulfate ester (DHEAS) decrease pro- (‘‘fountain of youth,’’ ‘‘miracle pill’’) or pseudoscientific asser- foundly with age, and the question is posed whether administration tion (‘‘mother hormone,’’ ‘‘antidote for aging’’) has led to of the steroid to compensate for the decline counteracts defects unfounded radical assertions, from superactivity (‘‘keep young,’’ associated with aging.
    [Show full text]
  • Treated with Steroids Derived from Dehydroepiandrosterone
    Proc. Natl. Acad. Sci. USA Vol. 92, pp. 6617-6619, July 1995 Medical Sciences Ergosteroids: Induction of thermogenic enzymes in liver of rats treated with steroids derived from dehydroepiandrosterone HENRY LARDY, BRUCE PARTRIDGE, NANCY KNEER, AND YONG WEI Institute for Enzyme Research, University of Wisconsin, 1710 University Avenue, Madison, WI 53705 Contributed by Henry Lardy, April 24, 1995 ABSTRACT Dehydroepiandrosterone (DHEA), an inter- above normal concentrations (16); they become hirsute and mediate in the biosynthesis of testosterone and estrogens, exhibit other signs of masculinization. exerts several physiological effects not involving the sex It was demonstrated by Tagliaferro et al. (20) that feeding hormones. When fed to rats it induces the thermogenic DHEA to rats enhanced heat production and decreased enzymes mitochondrial sn-glycerol-3-phosphate dehydroge- efficiency of food utilization. We therefore measured its effect nase and cytosolic malic enzyme in their livers. Animals and on the production of liver mitochondrial sn-glycerol-3- humans, and their excised tissues, are known to hydroxylate phosphate dehydrogenase and cytosolic malic enzyme, two DHEA at several positions and to interconvert 7a-hydroxy- enzymes that had been demonstrated (21-24) to be induced by DHEA, 7,8-hydroxy-DHEA, 7-oxo-DHEA, and the correspond- a classic thermogenic agent, the thyroid hormone. Both en- ing derivatives of androst-5-enediol. We report here that these zymes were increased severalfold in livers of rats fed a diet 7-oxygenated derivatives are active inducers of these thermo- containing 0.2-0.5% DHEA for 6 days (25, 26). A possible genic enzymes in rats and that the 7-oxo derivatives are more mechanism by which these enzymes function to decrease active than the parent steroids.
    [Show full text]
  • Improving Low Testosterone Naturally
    IMPROVING LOW TESTOSTERONE NATURALLY The following information is a summary of materials featured in the “Men’s Health” Whole Health overview. It is meant to be a quick reference for use at the point of care. For additional details and a list of helpful references, refer to the overview. Hormones change as we go through the life cycle. What is normal for a 20-year-old is not the same normal as for a 60-year-old. Although low testosterone ("low T") is a diagnosis being promoted by the makers of testosterone medications, it is not as simple as just prescribing hormone replacement. A low testosterone level can be due to many factors. A clinician must also take care not to add testosterone too quickly without exploring other therapies first, because once external testosterone is given, it inhibits the body's natural production of testosterone. Testosterone supplementation is also not without risks, and in terms of long-term use, there is much about safety that we do not yet know. KEY FACTORS IN OPTIMIZING MALE HORMONES MAINTAIN IDEAL BODY WEIGHT This is probably the most important thing a man can do. As belly fat increases, there is an increase in activity of the enzyme "aromatase" which converts testosterone in the fat cells to estrogen. This reduces testosterone and increases estrogen, which can increase fat deposition in typical female areas (breast, hips, thighs) and increase the risk of enlargement of the prostate and even prostate cancer. With every one-point drop in your body mass index (BMI) your testosterone level will increase by approximately 1 point.
    [Show full text]
  • Properties and Units in the Clinical Laboratory Sciences Part X
    Pure Appl. Chem., Vol. 72, No. 5, pp. 747–972, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART X. PROPERTIES AND UNITS IN GENERAL CLINICAL CHEMISTRY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, INGE IBSEN1, IVAN BRUUNSHUUS1, DESMOND KENNY2, RENÉ DYBKÆR3, XAVIER FUENTES-ARDERIU4, GILBERT HILL5, PEDRO SOARES DE ARAUJO6, AND CLEM McDONALD7 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Dublin, Ireland; 3Dept. of Standardisation in Laboratory Medicine, Kommunehospitalet, Copenhagen, Denmark; 4Dept. of Clinical Biochemistry, Ciutat Sanitària i Universitària de Bellvitge, Barcelona, Spain; 5Dept. of Clinical Chemistry, Hospital for Sick Children, Toronto, Canada; 6Dept. of Biochemistry, IQUSP, São Paolo, Brazil; 7Regenstrief Inst. for Health Care, Indiana University School of Medicine, Indianapolis, Indiana, USA #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994 to 1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996). Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada; 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H.
    [Show full text]